The new vaccine against the corona virus of China approved for commercialization is 79.34% | virus vaccine_Sina Finance_Sina.com

Original title: China’s new coronavirus vaccine approved for commercialization! The protection rate is 79.34%.

　　On the 31st, the Joint Prevention and Control Mechanism of the State Council held a press conference on the new coronavirus vaccine. At the meeting, it was announced that the inactivated Sinopharm China Bio-New Crown Vaccine had been approved by the State Food and Drug Administration for conditional inclusion. The protection rate of the vaccine was 79.34%.

　　China’s new coronavirus vaccine has been approved for commercialization! The protection rate is 79.34%.

　　Under the Joint Prevention and Control Mechanism of the State Council, the Sinopharm China Bio-New Crown Inactivated Vaccine has been approved by the State Food and Drug Administration for conditional inclusion.

　　After a series of strict reviews, reviews, verification, inspection and analysis of data in accordance with the law and procedures, it is concluded that the known and potential benefits of the new coronavirus inactivated vaccine from Sinopharm Zhongsheng Beijing Company are greater than those known and potential benefits. The risk has fully met the pre-established conditional listing standards, “announced Chen Shifei, deputy director of the State Drug Administration, at the meeting.

　　Existing data shows that the vaccine protection rate is 79.34%, achieving the unity of safety, effectiveness, accessibility and affordability, and complying with the relevant standards of the World Health Organization and the National Food Administration. and Medications.

　　In the future, the durability and protective effect of the immunity of the vaccine should be continuously observed. This achievement was hard earned. The inclusion of Chinese vaccines has injected confidence into the global fight against the epidemic and has also provided strong support for vaccines to become a global public product.

　　In terms of supervision, Chen Shifei also emphasized that after vaccines are conditionally put on the market, batch issuing agencies will implement strict data reviews and laboratory inspections on each batch of vaccines in accordance with relevant regulations and methods. management of batch issuance of biological products to ensure that each vaccine The vaccine is qualified.

　　14 vaccines in China have entered clinical trials

　　Xu Nanping, Vice Minister of Science and Technology, told the meeting that so far, 14 vaccines from 5 technical routes in China have entered clinical trials, of which 3 technical routes and 5 vaccines have entered phase III clinical trials.

　　Xu Nanping said: In the next step, we will continue to do our best to accelerate vaccine research and development, and we will not relax for a moment. One is to accelerate the advancement of phase III clinical trials and provide more vaccine products with different technical routes. The second is to pay close attention to global virus mutations and related developments, and to respond scientifically to ensure that vaccine use is not affected. Third, continue to increase basic research on vaccines, build a national strategic scientific and technological force, and provide strong scientific and technological support for the prevention and control of epidemics.

　　Over the past half month, cumulative vaccination of key populations across the country has exceeded 3 million doses.

　　Zeng Yixin, deputy director of the National Health Commission and head of the vaccine research and development team of the Joint Prevention and Control Mechanism of the State Council, presented at the meeting that in order to protect high-risk populations, in June of this year, in accordance with the “New Plan for the Emergency Use of the Coronavirus Vaccine” approved in accordance with laws and regulations. “China has adopted the principles of small-scale initiation, prudent and voluntary informed consent, and under the premise of adequate monitoring of adverse reactions and emergency treatment preparations, emergency vaccination of the new corona vaccine has been carried out. for high risk groups.

　　By the end of November, a total of more than 1.5 million doses had been vaccinated, and some 60,000 of them had gone to work in high-risk areas abroad. There were no reports of serious infections. The safety of the vaccine has been fully tested and its efficacy has also been verified. .

　　He said that to prevent the outbreak of the epidemic in the winter and spring, but also to effectively protect cold chain logistics personnel, customs border inspection personnel, disease control medical personnel, personnel of public transportation and some people at relatively high risk of infection, such as farmers markets and seafood markets. , China officially launched vaccination of key populations on December 15. In the past two months, cumulative vaccination of key populations across the country has exceeded 3 million doses.

　　The incidence of more serious adverse reactions is approximately two per million.

　　Zeng Yixin said that in the vaccination work, China has established a number of systems, such as comprehensive specifications for the establishment of the vaccination site, strict training of vaccination personnel, detection of recipients, monitoring of adverse reactions, emergency treatment and expert consultation for serious adverse reactions. To ensure the inoculation work is safe and smooth. This time, 3 million, plus the previous 1.5 million, fully demonstrated that the vaccine is safe.

　　He said that of course a certain proportion of adverse reactions occurred, the overall incidence is very close to inactivated vaccines that are routinely vaccinated, the main manifestations are some local pain and local induration. Less than 0.1% of mild fever cases and the incidence of more serious adverse reactions, such as allergic reactions, is approximately two per million. These conditions have been treated early and well.

　　“Therefore, we have repeatedly emphasized that we must clearly ask during vaccination, if there is a history of severe allergic reactions, and strict medical protection measures and medical units must be used during vaccination.”

　　Zeng Yixin emphasized that in addition, special attention should be paid to psychogenic reactions and incidents during vaccination. So-called psychogenic reactions are adverse reactions caused by psychological factors, such as those caused by being overly nervous. Coincident events refer to serious events that are intertwined with certain diseases or certain accidental factors during vaccination, which must be very vigilant and must be handled by professional staff in time.

　　He said that in the next step, with today’s approval of the conditional list, especially with the gradual improvement of the production and supply guarantee capacities, the vaccination of the elderly and high-risk groups with underlying diseases will be promoted in a comprehensive manner and ordered, and other populations will be followed in general. Vaccination.

　　At present, the China Immunization Program Expert Advisory Committee has formulated a unified vaccination plan. Through the orderly implementation of vaccination, all eligible people will be able to “get everything” and gradually build an immune barrier so that the entire population blocks the new crown. The spread of the virus has made it possible to thoroughly control the new corona pneumonia epidemic.

　　

Editor in charge: Deng Jian